Lepu medical acquires levosimendan injection, a new drug of haihetianhuo

Lepu medical announced on August 26 that the company plans to acquire 71.39% of the equity of Beijing haihetian Technology Development Co., Ltd for 125 million yuan to enter the field of heart failure drugs Among them, zuoximendan injection, the core of the latter, is a drug for the treatment of acute heart failure, and evidence-based medicine evidence shows that it is obviously superior to other drugs for the treatment of the same indications At present, only two approvals are issued by haihetian and Qilu pharmaceutical, and the sales price of Qilu pharmaceutical is around 2000 yuan The executive said that zuoximendan injection can be compared with the neokine of Tibet pharmaceutical industry, and the two drug markets are relatively close The sales volume of neokine last year was about 220 million, "we estimate that we can achieve 100 million sales after three years of efforts." The above-mentioned executives further said that the market of this drug has not yet been opened up, and it needs a professional sales team to sell Lepu has a very professional sales team for scientific promotion The company will set up a special sales team to sell the product and nesiritide purchased by the company at the beginning of the year The sales mode is similar to that of Lepu stent According to the analysis of Guojin Securities Research Report, the competition situation of zuoximendan is similar to that of clopidogrel Clopidogrel began to sell last year, with sales of 45.17 million in the first half of this year, and zuoximendan is expected to achieve explosive growth from next year Pu Zhongjie, President of the company, had previously said that it would step up its M & A efforts, focusing on the acquisition of large varieties and new varieties of drugs related to cardiovascular and diabetes About Lepu medical (Beijing) Medical Devices Co., Ltd was founded in 1999, with its headquarters in Changping Park, Zhongguancun Science and Technology Park, Beijing The company is a Sino foreign joint-venture high-tech enterprise controlled by the central government, which is engaged in the R & D, production and sales of cardiovascular disease interventional devices and equipment products, such as coronary drug stent, precordial occluder, heart valve and contrast machine It is one of the first 28 enterprises listed on the gem of Shenzhen Stock Exchange in 2009 At present, the company has 8 subsidiaries at home and abroad, with clinical application covering more than 1200 cardiac diagnosis and treatment centers across the country, and has developed into a leading domestic high-end medical product industry group of cardiovascular interventional diagnosis and treatment devices and equipment Haihetian Beijing haihetian Technology Development Co., Ltd ("Beijing haihetian") is located in the science and Technology Park, Changping District, Beijing It is a rapidly developing pharmaceutical technology company About zuoximendan zuoximendan, a class III new drug first approved for listing by Qilu pharmaceutical in China, "has been listed abroad, but has not been listed in China" According to Qilu pharmaceutical official response, zuoximendan was first listed in Sweden in September 2000, and is currently used in more than 50 countries, with a price of about $1000 each In comparison with other similar drugs in China, zuoximendan has one day of treatment, one dose per day, and the cost is 2600 yuan Before that, a more commonly used drug for heart failure has five days of treatment, five doses per day, and the total cost is 3375-4725 yuan